OTC · Medical - Pharmaceuticals

BioArctic AB (publ) (BRCTF) Stock

$31.78 -9.20% OTC: BRCTF Healthcare

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs.

Valuation

MetricValue
Price$31.78
Market Cap$2.82B
P/E Ratio125.73
P/B Ratio12.22
P/S Ratio23.40
EPS (TTM)$0.25
52-Week High$38.75
52-Week Low$19.34
Dividend Yield2.61%

Financials & Margins

MetricValue
ROE10.44%
ROA7.96%
ROCE17.34%
Gross Margin94.13%
Operating Margin34.50%
Net Margin18.59%
Debt/Equity0.02
Current Ratio6.54

Annual Financials (USD)

Metric20212022202320242025
Revenue$23.0M$228.0M$616.0M$257.0M$2.0B
Operating Profit$-140.0M$-17.0M$253.0M$-229.0M$1.4B
Net Profit$-120.0M$-11.0M$229.0M$-177.0M$1.0B
EPS$-1.36$-0.13$2.59$-2.00$11.52
Op Margin-603.7%-7.6%41.0%-88.8%68.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$898.0M$858.0M$1.2B$1.1B$2.6B
Total Liabilities$109.0M$72.0M$140.0M$217.0M$607.0M
Cash$848.0M$805.0M$612.0M$513.0M$1.0B
Borrowings$16.0M$10.0M$5.0M$54.0M$44.0M

Latest News

More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026 PR Newswire · Jul 14, 2026 FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease PR Newswire · Jul 14, 2026 New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease PR Newswire · Jul 13, 2026 New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026 PR Newswire · Jun 30, 2026 Eli Lilly (LLY) and BioArctic AB Enter into Research and Collaboration Agreement Insider Monkey · Jun 27, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-140.0M$-32.0M$310.0M$-316.0M$1.4B
Investing Cash Flow$-9.0M$-26.0M$-515.0M$179.0M$-903.0M
Financing Cash Flow$-7.0M$-9.0M$-1.0M$0$0
Net Cash Flow$-152.0M$-43.0M$-194.0M$-99.0M$612.0M
Free Cash Flow$-145.0M$-44.0M$302.0M$-343.0M$1.4B

Valuation & Return Ratios

MetricValue
PEG Ratio-1.65
EV / EBITDA62.47
FCF Yield4.67%
Quick Ratio6.54
Interest Coverage16.36
Return 1Y73.27%
Return 3Y23.38%
Return 5Y—

Ownership

Insiders Held42.68%
Institutions Held34.34%
Institutions Float Held59.90%
Institutional HolderSharesReport Date
Nbc Securities, Inc. 1252026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About BioArctic AB (publ)

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

BioArctic AB (publ) is headquartered in SE.

BioArctic AB (publ) (BRCTF) stock trades at $31.78 with a market capitalization of $2.82B. The stock is valued at a price-to-earnings (P/E) ratio of 125.73, price-to-book of 12.22, price-to-sales of 23.40. Over the past 52 weeks the stock has ranged between $19.34 and $38.75, and currently trades 18.0% below its 52-week high. It pays a dividend yielding 2.61%.

On profitability, BioArctic AB (publ) generates a return on equity (ROE) of 10.44%, return on capital employed of 17.34%, an operating margin of 34.50%, a net profit margin of 18.59%.

Official website: www.bioarctic.se

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides